Non-Current Assets
Deferred Tax Assets
Regeneron Pharmaceuticals Deferred Tax Assets increased by 2.8% to $4.19B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 21.7%, from $3.44B to $4.19B. Over 5 years (FY 2020 to FY 2025), Deferred Tax Assets shows an upward trend with a 36.5% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryRisk
SignalContext dependent
VolatilityModerate
First reportedQ4 2017
Last reportedQ1 2026Apr 29, 2026
How to read this metric
An increase may indicate past operating losses or tax credits that provide a future buffer, while a decrease suggests the utilization of these benefits to offset tax liabilities.
Detailed definition
This represents the future tax benefits that the company expects to realize due to temporary differences between the fin...
Peer comparison
Standard across all industries; levels depend heavily on the company's historical profitability and tax jurisdiction profile.
Metric ID:
non_current_assets_deferred_income_tax_assets_netHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $746.60M | $723.20M | $876.90M | $1.14B | $1.35B | $1.45B | $1.72B | $1.92B | $2.14B | $2.32B | $2.58B | $2.76B | $2.88B | $3.02B | $3.31B | $3.44B | $3.57B | $3.85B | $4.08B | $4.19B |
| QoQ Change | — | -3.1% | +21.3% | +30.0% | +18.6% | +7.4% | +18.7% | +11.7% | +11.1% | +8.3% | +11.2% | +7.4% | +4.2% | +4.7% | +9.9% | +3.9% | +3.8% | +7.7% | +6.0% | +2.8% |
| YoY Change | — | — | — | — | +81.1% | +100.8% | +96.6% | +68.8% | +58.1% | +59.5% | +49.4% | +43.6% | +34.7% | +30.1% | +28.7% | +24.5% | +24.0% | +27.6% | +23.0% | +21.7% |
Range$723.20M – $4.19B
CAGR+43.8%
Avg YoY Growth+48.3%
Median YoY Growth+39.2%
Current Streak18 quarters growth
Deferred Tax Assets at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's deferred tax assets?
- Regeneron Pharmaceuticals (REGN) reported deferred tax assets of $4.19B in Q1 2026.
- How has Regeneron Pharmaceuticals's deferred tax assets changed year-over-year?
- Regeneron Pharmaceuticals's deferred tax assets increased by 21.7% year-over-year, from $3.44B to $4.19B.
- What is the long-term trend for Regeneron Pharmaceuticals's deferred tax assets?
- Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's deferred tax assets has grown at a 36.5% compound annual growth rate (CAGR), from $858.90M to $4.08B.
- What does deferred tax assets mean?
- Future tax savings the company expects to realize based on past financial activities.